Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected
about
HIV-1 entry inhibitors: recent development and clinical useRecent developments in human immunodeficiency virus-1 latency researchA highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialReliable genotypic tropism tests for the major HIV-1 subtypesThe CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1Can early therapy reduce inflammation?Persistent immune activation in chronic HIV infection: do any interventions work?Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cellsEarly but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized TrialRole of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapyMaraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.Effect of maraviroc on HIV disease progression-related biomarkers.CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infectionOnce-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cellsLack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.Thirty years of the human immunodeficiency virus epidemic and beyond.Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Residual inflammation and viral reservoirs: alliance against an HIV cure.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionDivergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection.Preclinical discovery and development of maraviroc for the treatment of HIV.Therapeutic imprinting of the immune system: towards a remission of AIDS in primates?Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.Expression of gut-homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV-1-infected patients?Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.HIV as a Cause of Immune Activation and Immunosenescence.
P2860
Q27003887-FB2F9A6B-3744-401D-9CB1-03F85B957552Q27013114-3C27ED30-2C2E-47BC-8FDD-13FD7A9F3BCCQ27344720-ABA5D582-A562-4C96-9641-1933D95FC09AQ27687272-7FA01432-A0C9-4437-AE39-5A849D4D7757Q28552729-6B4F3257-2FDA-414C-A4FC-2DEB52D3EC60Q30372085-5BF9EFC2-A295-4781-A384-61E7808EEA45Q33725916-85A226DE-21EF-42AF-BFC7-EDB5CA988CACQ34159822-66D821FF-2E2A-47C6-9E76-DE88EDA0AD9AQ34851102-8FE60C67-0CC2-4E78-AA2F-6445A999B878Q35111879-75DD7FA4-AF7F-491D-AAB1-0FE551E987F8Q35630665-72BF66D5-03A2-4E90-B77C-2E365F8DC1B4Q35712284-263AE0FC-F771-442D-9366-FAAFA137BE4AQ35904344-5796A17A-AC83-46D0-814E-C4885C912C8CQ36171658-D639B574-6E65-4530-80E8-43D11C1BE641Q36263361-0E3972D3-D0FC-4BBA-9DC6-CEEECBC89071Q36364075-74C82017-065C-40AF-9081-E1E26BAA25C7Q36434337-3AF99414-3127-45A3-8789-42BBE72F6C6EQ36868170-27BDB949-C34F-42A7-A5D0-302820AF9DC2Q36938539-997E7EBC-9F39-4C22-9CF2-D01EF0FAAFC0Q37098066-F217C2B9-141C-4BF9-A839-D257F8D3CE71Q37098356-829167E8-FD71-4D0D-AD76-B1565DB4DE6FQ37109010-F9B42782-5BA9-4307-8232-178E038F726DQ37141282-CEF3551F-BF32-43B1-B39A-5A173E4903DFQ37145779-1ABA4951-E10C-4134-8D29-0E7DA2023A7CQ37418140-94B7C18E-1825-467A-9C3F-28F80C845B55Q37521828-0181DF9A-BD9D-4F45-B61E-A8FC2E41CE15Q37667360-29A54EAE-1326-478A-8EAB-5790FB0184F8Q38066127-46B15A7C-7CED-432D-9C70-8920342C3058Q38196457-24E67BBB-14D3-43E6-A959-546B42AB1760Q38269458-3431395A-DF3D-4E8E-9507-D7FB4927F818Q38574172-2D4271EA-C598-42BB-A9EA-0B4D64DFA798Q38702121-9193E09A-9B77-456B-8FC7-379CF84A6702Q38749963-7C5A0DB5-C415-4AB7-8D9F-43AE4EFC242CQ39335635-6D72206B-AFAF-4CA8-9AED-661945BDBF77Q39556338-97CBD4CF-97AF-4CC6-B44C-D670CDF5D4EBQ41814233-C4F5BB29-DE50-4499-9CDB-D507DB4A8B00Q41989387-FAF67F64-DCD1-4038-A510-7EAC445F5E98Q42215126-CF2CB196-C538-4BB4-9F46-27A4D5E95587Q42226567-74CA7E71-2B03-4732-99E2-A3E257590134Q47151081-C8C2C60A-B6B9-41CD-8E05-4B5731B39B9C
P2860
Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Intensification of antiretrovi ...... t on T cells latently infected
@ast
Intensification of antiretrovi ...... t on T cells latently infected
@en
Intensification of antiretrovi ...... t on T cells latently infected
@nl
type
label
Intensification of antiretrovi ...... t on T cells latently infected
@ast
Intensification of antiretrovi ...... t on T cells latently infected
@en
Intensification of antiretrovi ...... t on T cells latently infected
@nl
prefLabel
Intensification of antiretrovi ...... t on T cells latently infected
@ast
Intensification of antiretrovi ...... t on T cells latently infected
@en
Intensification of antiretrovi ...... t on T cells latently infected
@nl
P2093
P2860
P50
P3181
P1433
P1476
Intensification of antiretrovi ...... t on T cells latently infected
@en
P2093
Ana M Moreno
Beatriz Hernández-Novoa
Carolina Gutiérrez
Eduardo Muñoz
Enrique Navas
Fernando Dronda
José Luis Casado
Laura Díaz
María Abad
María Jesús Pérez-Elías
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0027864
P407
P577
2011-01-01T00:00:00Z